Financière de Tubize SA
27.2.2021 08:01:37 CET | Globenewswire | Press release
FINANCIERE DE TUBIZE SA/NV
Allée de la Recherche 60, 1070 Brussels
Contact: Anne Sophie Pijcke, directeur, aspijcke@financiere-tubize.be
Annual financial report 2020
Regulated information
27 February 2021
The board of directors of Financière de Tubize has established the 2020 annual financial report. This report is available on the website www.financiere-tubize.be
- Dividend received from UCB: € 84,4 million (against € 82.4 million in 2019)
- Profit of € 81,0 million (against € 80.0 million in 2019)
- Decrease of outstanding debt from € 86.5 million at 31 December 2019 to € 33,5 million at 31 December 2020.
If the general shareholders meeting of 30 April 2021 approves the 2020 annual accounts, including the proposed result appropriation, a dividend of € 0,68 will be payable as from 6th of May 2021 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 16.
Ex-dividend 4 May 2021
Record date 4 May 2021
Payment date 6 May 2021
In addition, the company Other Look SRL (Ol2EF) represented by Mrs Anne-Sophie Pijcke has given its resignation with effect at the end of the Ordinary General Assembly on 30 April 2021. The new Director of the Company will, from that date, be the company ENRE SRL, represented by its director Mr. Eric Nys, whose head office is established Place Obert de Thieusies at 7830 Silly, which will carry out missions similar to those previously devolved to Ol2EF SRL.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
Vivoryon Therapeutics N.V.28.3.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
